Candidates for robotic gastrectomy include patients with gastric adenocarcinoma, gastrointestinal stromal tumors, or genetic risks requiring prophylactic stomach removal. These individuals benefit from precise, minimally invasive resections using Da Vinci technology in JCI-accredited Spanish centers, facilitating faster recovery than traditional open surgery.
- Cancer stage: Ideal for early-stage adenocarcinoma where tumors have not deeply invaded organs.
- Genetic risk: Patients with CDH1 mutations requiring preventive total gastrectomy for cancer avoidance.
- Physical profile: Individuals with a Body Mass Index (BMI) typically under 35 ensure optimal maneuverability.
- Surgical history: Candidates without extensive prior abdominal surgeries to avoid complications from internal adhesions.
- System availability: Patients confirmed for treatment at facilities with Da Vinci Xi or 5 platforms.
Bookimed Expert Insight: Spain offers a unique concentration of award-winning expertise, such as Dr. Cesar Canales Bedoya, a Forbes-ranked surgeon with 30 years of experience. While US costs average $63,000, choosing these top-rated Spanish experts provides up to 71% savings for identical robotic technology.
Patient Consensus: Patients emphasize verifying the specific robotic platform available, as advanced systems like the Da Vinci Xi significantly influence the precision of lymph node removal.